Background Methamphetamine (MA) use is disproportionately higher among people living with HIV (PWH) and contributes to adverse clinical outcomes. Accurate measurement of MA use is essential for research and care but remains inconsistent. Methods A systematic review of PubMed, Embase, and CINAHL identified 22 peer-reviewed studies (2019-2024) assessing MA use in HIV-positive adults. Data were extracted on measurement methods, demographic composition, and HIV outcomes. Results Studies employed self-report, urine or hair toxicology, and medical record review. Reporting varied widely in timeframe, frequency, and specificity, with limited detail on route of administration. Most studies were U.S.-based, disproportionately male, and rarely included women or gender-diverse participants. Inconsistent definitions and reliance on broad stimulant categories limited comparability. Conclusions Current methods for assessing MA use in PWH lack standardization. Greater consistency, inclusion of biological validation, and expanded demographic representation are needed to strengthen research and clinical interventions.
Margaret White (Thu,) studied this question.